Drug-Device Combination Products: 4 Evolving Platforms For 2026

By Andrey Meshcheryakov, Recombinators

Biologic drug delivery is entering a new phase. For years, the industry’s center of gravity was the molecule itself: potency, selectivity, durability, immunogenicity. In 2026, that is no longer enough. The device, the formulation, the data layer, and the care setting are becoming part of the product strategy. That shift is visible across recent biologic-device combination product reviews, which show how prefilled syringes and autoinjectors became dominant formats while dual-chamber systems, on-body injectors, and smart connected devices have moved from niche concepts into increasingly credible platform plays.¹

What matters now is not just whether a drug can be injected, but how elegantly the entire experience can be packaged around the patient, the provider, and the supply chain. Four platform families stand out in 2026:

• Microneedle transdermal systems
• Dual-chamber reconstitution autoinjectors
• Wearable on-body injectors
• Smart autoinjectors

Each solves a different friction point. One reduces pain and potentially simplifies deployment. One tames unstable formulations. One moves large-volume biologics out of infusion centers. One turns self-injection from a blind event into a measurable digital workflow. Taken together, they point to a simple conclusion: delivery technology is becoming a primary lever of competitive advantage, not a secondary packaging choice.

Microneedle Systems Are No Longer Just A Novelty

Microneedles have been discussed for years as a “needle-free future,” but 2026 looks more like the beginning of platform stratification than a single breakthrough moment. The science is attractive for familiar reasons: microneedles are minimally invasive, can bypass first-pass metabolism, help maintain more stable plasma levels, and may improve bioavailability, safety, and patient compliance. For biologics and vaccines, they also offer a potentially user-friendly alternative to conventional injection routes that often depend on trained personnel and sharps management.

The important nuance is that “microneedles” are not one thing. The platform family now includes solid, coated, dissolvable or biodegradable, and hollow microneedles, each with different strengths and trade-offs.² Solid microneedles can be attractive because they may work with existing formulations, but dose control can be harder. Coated and dissolving systems push the dose into the array itself, which can improve stability and user simplicity, although manufacturing becomes more exacting. Hollow systems are effective for direct liquid delivery but do not solve liquid stability or cold chain constraints on their own. In other words, the real wave is not a single winner-take-all design. It is the growing realization that different microneedle architectures fit different molecules and market needs.

Clinical and translational progress is now tangible enough to matter strategically. Vaxxas’ HD-MAP program has already reported a Phase 1 measles-rubella vaccine trial, described as the first clinical study using its HD-MAP with an integrated applicator similar to the one envisioned for commercial use.⁶ Vaxxas also describes its platform as productized for commercial use, validated in human clinical studies, and designed for manufacture at scale. That does not mean microneedle patches are suddenly a mature mass market across all therapeutic categories. It does mean they have crossed the line from speculative concept to serious platform contender.

What makes microneedles especially interesting in 2026 is the operational upside. A 2025 qualitative study in older adults found that high-density microarray patches were perceived as convenient, suitable for self-administration, and potentially useful in low-resource settings because of thermostability and reduced dependence on healthcare personnel.⁷ That is exactly why pharma strategists should care. A better patch is not just a nicer patient experience; it can also change who administers the product, where it is administered, and what the commercial model looks like.

There is also real evidence that manufacturability is moving from theory to practice. PDA’s 2025 review of microneedle array patches highlighted a coated microneedle abaloparatide program that reached Phase 3, produced more than 200,000 coated arrays for the trial, and led to the design of a commercial-scale line with an annual capacity of roughly 14 million units.⁴ That is a meaningful signal. It suggests the microneedle conversation is shifting from “can this work?” to “which products are worth industrializing?”

Still, the barriers are not trivial. Sterilization remains a regulatory-critical issue, manufacturing equipment is not yet standardized, and quality control depends on consistent geometry, puncture performance, drug loading, and packaging integrity.⁵ So, the near-term winners are likely to be products where the patient value story and the manufacturing story are both unusually strong. In 2026, microneedles are making waves not because every patch is ready but because enough of the platform now is.

Dual-Chamber Reconstitution Autoinjectors

If microneedles solve pain and deployment, dual-chamber autoinjectors solve instability. Many biologics and peptides are still difficult to keep stable in liquid form for the shelf-life and distribution profile the market wants.⁹ Lyophilization remains one of the most widely used ways to stabilize heat-sensitive and liquid-unstable protein products, and recent reviews still describe dual-chamber systems as a key container closure option because they enable direct reconstitution at the point of use.⁸

There is a clear historical precedent here. Albiglutide, marketed as Tanzeum, used a dual-chamber prefilled injection pen containing lyophilized powder and diluent, with reconstitution before administration.¹⁰ That mattered because it showed the industry a path: if a biologic cannot live comfortably as a simple liquid in a standard pen, the device itself can take on part of the formulation burden. The product may have exited the market for other reasons, but as a design precedent, it remains highly relevant.

The difference in 2026 is how directly device companies are productizing that lesson. SHL Medical’s Reunite is an easy-to-use dual-chamber cartridge autoinjector designed for automated reconstitution and delivery of lyophilized formulations. The device’s three-step sequence – unlock, twist, push – is explicitly aimed at reducing the risks of manual mixing and dosing.^11,12,13 Ypsomed’s LyoTwist, described in February 2026 as available for licensing, is likewise built as a dual-chamber monodose device intended to simplify reconstitution and injection while giving the user clear feedback through the process.

That makes dual-chamber systems more important than they may appear at first glance. They are not just convenience devices. They are enabling platforms for formulations that otherwise stay trapped in vials, clinics, or cumbersome preparation steps. In effect, they extend the precedent of the prefilled syringe into more complex territory: not “ready to inject” in the classic sense, but “ready to become injectable” with a much safer, more controlled last mile workflow.

The strategic implication is powerful. As more high-value, structurally sensitive biologics move toward self-administration, the device that best hides complexity may become the preferred commercial route. A dual-chamber autoinjector can turn lyophilization from a pharmaceutical necessity into a patient-manageable experience. That opens the door to home administration, cleaner instructions for use, and tighter control of dosing risk. In other words, these systems may do for unstable biologics what prefilled syringes once did for relatively straightforward injectables: reduce friction enough to unlock scale.

Wearable Injectors: High-Volume Biologic Care Decentralization

On-body injectors may be the clearest example of site-of-care strategy becoming device strategy. Their core value proposition is straightforward: they enable doses above the comfort zone of a classic handheld injector. A 2025 review notes that on-body drug delivery systems can deliver doses exceeding 2 mL at precisely controlled rates and durations.² That matters because conventional self-injection becomes much less elegant as volume rises, viscosity increases, and injection time lengthens.

The commercial signal is already visible. BD’s Libertas wearable injector is designed for home or clinical use, supports biologics up to 50 cP, and comes in 2 to 5 mL and 5 to 10 mL configurations.¹⁴ In July 2025, BD announced the first pharma-sponsored combination product clinical trial using Libertas for subcutaneous delivery of complex biologics.¹⁵ The company framed the opportunity exactly the way the market now sees it: conversion of therapies that traditionally require travel to hospitals or clinics into more flexible care settings, including home self-injection.

Enable Injections offers another strong marker of platform maturity. Its approvals page states that the FDA approved the EMPAVELI Injector combination product, based on enFuse technology, for at-home self-administration with a specific drug, and the company notes EU MDR CE mark approval for certain enFuse configurations in clinical use.^16,17 The earlier FDA approval announcement for the EMPAVELI Injector described it as a compact, wearable, on-body system for large-volume subcutaneous delivery designed to streamline self-administration with minimal disruption to daily life.

The category is also broadening beyond traditional specialty biologics. In October 2025, Lasix ONYU received FDA approval as a drug-device combination for edema in adults with chronic heart failure.^18,19 Its infusor is preprogrammed to deliver 30 mg in the first hour and then 12.5 mg per hour for the next four hours. That is notable because it shows on-body infusion moving into practical at-home management of fluid overload, not just into rare disease or biologic maintenance therapy. Once a platform can credibly shift even part of treatment from hospital to home, it has strategic weight far beyond the device bill of materials.

The patient experience upside is obvious: less clinic time, fewer IV-style visits, and more flexible scheduling. But the bigger story is system economics. Wearable injectors can help pharma convert large-volume or slow-delivery therapies into subcutaneous regimens with less dependence on infusion infrastructure. That can reduce burden on clinics, expand treatment capacity, and make a therapy more attractive to both patients and payers. In 2026, on-body injectors are making waves because they do not just administer drugs differently; they reorganize where care happens.

Smart Autoinjectors: From Gadgets To Real Clinical Utility

The most overused word in drug delivery may be “smart.” For a long time, connected injectors sounded futuristic but thin: a Bluetooth layer in search of a use case. That is changing. What is becoming real in 2026 is not flashy consumer tech theater. It is objective, therapy-relevant injection data. Ypsomed’s SmartPilot crossed an important threshold when it received FDA 510(k) clearance in 2025.^20,21,22 The company says the add-on transforms YpsoMate into a connected system that automatically captures and transmits injection data, including time and date, injection outcome, and potential user errors. It also describes SmartPilot as the first FDA-cleared connectivity device specifically designed for use with an autoinjector platform.

That matters because it changes the status of self-injection from a largely invisible event into a measurable one. The FDA summary for SmartPilot describes it as an injection data capture device that records device data, injection data, and process status while guiding the user through the injection. In the supporting human factors validation study, the accessory sensed spring movements of the inserted autoinjector, translated them into visual and auditory step-by-step guidance, detected errors such as partial injection or insufficient holding time, and transmitted data to a digital therapy management system for remote adherence monitoring. That is not a gimmick. It is the foundation of a feedback loop.

The broader connected-injection ecosystem is also clarifying what “smart” will probably mean in practice. A medmix-AARDEX connected pen-cap system describes identifying the actual expelled dose by comparing plunger position before and after injection using infrared sensing.²³ In diabetes, Medtronic’s MiniMed Go received FDA clearance in January 2026 as a smart MDI (multiple daily injections) system integrating insulin dosing and glucose data in a single app.²⁴ Those are not autoinjectors, but they show where the market is headed: toward dosing records that are automatic rather than self-reported, and toward digital layers that can support reminders, coaching, and clinician visibility.

That is why the most important question for smart autoinjectors in 2026 is not whether they can connect. It is whether they can reduce real failure modes: missed doses, incomplete doses, incorrect hold time, poor onboarding, and weak adherence visibility in clinical trials or chronic therapy. On that standard, the category is beginning to look materially more mature. In the near term, schedule tracking and injection success logging appear to be the core use cases. Site rotation support will likely live mostly in the companion app layer rather than in the disposable hardware itself. But the direction is clear: self-injection devices are becoming data-generating endpoints, not just delivery tools.

The Bigger Pattern

The four waves are different, but they are converging on the same strategic outcome. Microneedles reduce procedural burden and may simplify deployment. Dual-chamber autoinjectors make unstable formulations more self-administration-friendly. Wearable on-body injectors move high-volume delivery into home or low-touch settings. Smart autoinjectors make therapy use observable, coachable, and increasingly auditable. None of these platforms wins simply because the engineering is elegant. They win when they remove a bottleneck somewhere else in the system.

That is the real 2026 story. Combination products are no longer peripheral wrappers around the molecule. They are becoming part of the molecule’s commercial logic. The next competitive advantage in biologics will not come only from better biology. It will also come from better last mile design: less mixing, less pain, less clinic dependency, less uncertainty, and more proof that the dose was actually delivered as intended. The companies making waves now are the ones treating delivery platforms as strategic infrastructure rather than packaging afterthoughts.

References